These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22571655)

  • 1. Radiolabeled small molecule inhibitors of VEGFR - recent advances.
    Kniess T
    Curr Pharm Des; 2012; 18(20):2867-74. PubMed ID: 22571655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials.
    Zhang C; Tan C; Ding H; Xin T; Jiang Y
    Curr Pharm Des; 2012; 18(20):2921-35. PubMed ID: 22571661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.
    Niu G; Chen X
    Curr Drug Targets; 2010 Aug; 11(8):1000-17. PubMed ID: 20426765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
    Wilson PM; LaBonte MJ; Lenz HJ
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).
    Peng FW; Liu DK; Zhang QW; Xu YG; Shi L
    Expert Opin Ther Pat; 2017 Sep; 27(9):987-1004. PubMed ID: 28621580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.
    Melincovici CS; Boşca AB; Şuşman S; Mărginean M; Mihu C; Istrate M; Moldovan IM; Roman AL; Mihu CM
    Rom J Morphol Embryol; 2018; 59(2):455-467. PubMed ID: 30173249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel anti-angiogenic therapies for malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF in nuclear medicine: Clinical application in cancer and future perspectives (Review).
    Taurone S; Galli F; Signore A; Agostinelli E; Dierckx RA; Minni A; Pucci M; Artico M
    Int J Oncol; 2016 Aug; 49(2):437-47. PubMed ID: 27277340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor: biology and therapeutic applications.
    Ho QT; Kuo CJ
    Int J Biochem Cell Biol; 2007; 39(7-8):1349-57. PubMed ID: 17537667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VEGF as a potential target in lung cancer.
    Frezzetti D; Gallo M; Maiello MR; D'Alessio A; Esposito C; Chicchinelli N; Normanno N; De Luca A
    Expert Opin Ther Targets; 2017 Oct; 21(10):959-966. PubMed ID: 28831824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
    Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
    J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases.
    Fallah A; Sadeghinia A; Kahroba H; Samadi A; Heidari HR; Bradaran B; Zeinali S; Molavi O
    Biomed Pharmacother; 2019 Feb; 110():775-785. PubMed ID: 30554116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-angiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors.
    Cheng K; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(13):2540-2564. PubMed ID: 32407259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current overview of angiogenesis inhibitors.
    Ellis LM
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery.
    Chimote G; Sreenivasan J; Pawar N; Subramanian J; Sivaramakrishnan H; Sharma S
    Drug Des Devel Ther; 2014; 8():1107-23. PubMed ID: 25170251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
    Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
    Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
    Ferrara N; Hillan KJ; Novotny W
    Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
    Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
    Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-angiogenic alternatives to VEGF blockade.
    Khan KA; Bicknell R
    Clin Exp Metastasis; 2016 Feb; 33(2):197-210. PubMed ID: 26620208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.